As per the exclusive license agreement, Genor to lead clinical development, regulatory submissions and commercialisation of lerociclib in Asia-Pacific.
An open-label, multi-dose, dose-escalation, and dose-expansion Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour efficacy of CS3002 in patients with advanced solid tumours